The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD
Recruiting · NCT06474039 · Interventional (participants receive a specific treatment) · Lead sponsor: Mahidol University
View the official record on ClinicalTrials.gov →Interventions studied
Trelegy or Anoro
What this trial is about
This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators
Who can take part
Age range
40 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients who have met the criteria for COPD GOLD B defined by an exacerbation not more than 1 time in the last year prior to the study enrollment. These patients will be recruited in sequential sequence.
- Patients with COPD GOLD B are previously treated with either LAMA or LAMA/LABA or short-acting bronchodilators
- Patients who are able to provide informed consent.
Exclusion criteria
- \- Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung, other malignancy, active heart diseases.
- Receiving long-term treatment with immunosuppressive drugs and systemic corticosteroids
- Being treated with triple therapy (ICS/LABA/LAMA)
- Being in terminally ill conditions
Where it is running
1 location listed.
- Division of Respiratory Disease and TB, Siriraj Hospital - Bangkoknoi, BKK, Thailand